Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "LAR1:gu ;lar1:(lu);pers:(Minthon Lennart 1951)"

Sökning: LAR1:gu > Lunds universitet > Minthon Lennart 1951

  • Resultat 1-10 av 16
Sortera/gruppera träfflistan
  • Andersson, Malin E, 1978-, et al. (författare)
  • Kinesin gene variability may affect tau phosphorylation in early Alzheimer's disease.
  • 2007
  • Ingår i: International journal of molecular medicine. - 1107-3756. ; 20:2, s. 233-9
  • Tidskriftsartikel (refereegranskat)abstract
    • Kinesin is a microtubule-associated motor protein that transports Alzheimer-associated amyloid precursor protein (APP) in neurons. In animal models, impaired kinesin-mediated APP transport seems to enhance formation of the neurotoxic 42 amino acid fragment of beta-amyloid (A beta 42). In man, one study suggests that a polymorphism (rs8702, 56,836G > C) in the kinesin light chain 1 gene (KNS2) may affect the risk of Alzheimer's disease (AD). To further assess KNS2 as a susceptibility gene for AD we analyzed 802 patients with sporadic AD and 286 controls, 134 longitudinally followed patients with mild cognitive impairment (MCI) and 39 cognitively stable controls for the rs8702 polymorphism. The rs8702 polymorphism did not influence risk of AD (p=0.46). However, rs8702 interacted with APOE epsilon 4 carrier status in AD (p=0.006) and influenced cerebrospinal fluid levels of hyper-phosphorylated tau in MCI patients who converted to AD during follow-up (p=0.018). These findings support earlier indications that genetic variability in the KNS2 gene may play a role during early stages of AD pathogenesis.
  • Boström, Fredrik, et al. (författare)
  • Cerebrospinal Fluid Total Tau Is Associated with Shorter Survival in Dementia with Lewy Bodies.
  • 2009
  • Ingår i: Dementia and Geriatric Cognitive Disorders. - 1420-8008 .- 1421-9824. ; 28:4, s. 314-319
  • Tidskriftsartikel (refereegranskat)abstract
    • A pathology typical of dementia with Lewy bodies (DLB) has been demonstrated to increase mortality to a greater extent than the pathology of Alzheimer's disease (AD). However, mortality in DLB has also been shown to increase with concomitant AD pathology. Furthermore, in a recent publication, we showed that there is a robust and specific increase in CSF calcium and magnesium in DLB patients compared to both AD patients and controls. Thus, in order to explore the influence of CSF AD markers and trace element concentrations on mortality in DLB, we undertook a longitudinal prospective study of 47 clinically diagnosed DLB patients and 157 AD patients as well as 49 healthy volunteers. Both AD and DLB patients showed an increased mortality compared to the healthy controls (relative risk: 10 and 8, respectively; p < 0.001). Increased levels of CSF total tau were associated with increased mortality among the DLB patients (p < 0.05), but not among the AD patients or controls. Gender, age, MMSE score, Abeta42 concentration and phosphorylated tau, and CSF trace element concentrations did not influence survival in the obtained models.
  • Buchhave, Peder, et al. (författare)
  • Elevated plasma levels of soluble CD40 in incipient Alzheimer's disease.
  • 2009
  • Ingår i: Neuroscience letters. - 0304-3940. ; 450:1, s. 56-9
  • Tidskriftsartikel (refereegranskat)abstract
    • CD40 is a member of the tumor necrosis factor receptor super-family and has been suggested to play a role in the metabolism of beta-amyloid (Abeta) in Alzheimer's disease (AD). However, the role of CD40-signalling in incipient AD has not yet been studied. We investigated the plasma levels of soluble CD40 (sCD40) and the soluble CD40 ligand (sCD40L) at baseline in 136 subjects with mild cognitive impairment (MCI) and 30 age-matched controls. Sixty of the 136 MCI cases converted to AD (MCI-AD) during a clinical follow-up period of 4-7 years. The baseline levels of sCD40, but not sCD40L, were elevated in MCI-AD cases when compared to age-matched controls (Mann-Whitney U-test, p=0.02). However, MCI patients who were cognitively stable or developed vascular dementia during follow-up did not have significantly increased levels of sCD40 or sCD40L when compared to controls. The levels of sCD40 correlated to decreased baseline performance on mini-mental state examination (MMSE) in both controls (r(s)=-0.37, p<0.05) and MCI-AD cases (r(s)=-0.29, p<0.05). Finally, the plasma levels of sCD40 correlated with the levels of soluble amyloid precursor protein-alpha (sAPP-alpha) (r(s)=0.28, p<0.01) and sAPP-beta (r(s)=0.23, p<0.05) in cerebrospinal fluid. In conclusion, CD40-signalling might play a role in the pathogenesis of early AD.
  • Gerhardsson, Lars, 1952-, et al. (författare)
  • Concentrations of metals, beta-amyloid and tau-markers in cerebrospinal fluid in patients with Alzheimer's disease.
  • 2009
  • Ingår i: Dementia and geriatric cognitive disorders. - 1421-9824. ; 28:1, s. 88-94
  • Tidskriftsartikel (refereegranskat)abstract
    • Background/Aims: In this study, metal concentrations were related to the levels of well-known Alzheimer markers in cerebrospinal fluid (CSF), such as amyloid-beta (A beta), total tau (T-tau) and phosphorylated-tau (P-tau). Methods: Concentrations of 19 metals (Mg, Ca, V, Mn, Fe, Co, Ni, Cu, Zn, Se, Rb, Sr, Mo, Cd, Sn, Sb, Cs, Hg and Pb by inductively coupled plasma-mass spectrometry) and the levels of A beta, T-tau and P-tau in CSF were determined (xMAP technology) in 264 patients with Alzheimer's disease ( AD), and in 54 healthy referents. Results: The AD subjects showed positive correlations between CSF-T-tau and CSF-P-tau versus CSF-Mn (r(s) = 0.22, p = 0.004; r(s) = 0.18, p = 0.021). CSF-T-tau, however, showed a negative correlation with CSF-Cs (r(s) = -0.17; p = 0.027). In subjects with severe AD, CSF-A beta showed a strong positive correlation with CSF-Cs (r(s) = 0.49; p = 0.026), while CSF-T-tau showed a strong negative correlation with CSF-Cs (r(s) = -0.49; p = 0.026). Also, CSF P-tau was negatively associated with CSF-Cs (r(s) = -0.41; p = 0.06). Conclusion: The different relationships between the CSF-levels of A beta and tau-markers versus the levels of CSF-Mn and CSF-Cs may be due to different binding affinity between these metals and metal binding proteins in the CSF and the surrounding brain. Copyright (c) 2009 S. Karger AG, Basel
  • Landgren, Sara, 1980-, et al. (författare)
  • No Association of VEGF Polymorphims with Alzheimer's Disease.
  • 2010
  • Ingår i: Neuromolecular medicine. - 1559-1174. ; 12:3, s. 224-8
  • Tidskriftsartikel (refereegranskat)abstract
    • The vascular hypothesis of Alzheimer's disease (AD) has brought the vascular endothelial growth factor (VEGF) into focus. The genomic region including the VEGF gene has been linked to AD and single nucleotide polymorphisms (SNPs) of the VEGF have in previous studies been associated with AD risk. To further evaluate these findings, we genotyped two SNPs in the VEGF gene (rs699947 [-2578]) and rs1570360 [-1154]) by TaqMan Allelic Discrimination in a study sample including AD patients (n = 801) and controls (n = 286). In a subgroup of the population these SNPs were analyzed in relation to APOE epsilon 4 genotype, to cerebrospinal fluid biomarkers (T-tau, P-tau, and beta(42)-Amyloid) as well as to neuropathological markers for AD (neurofibrillary tangles and senile plaques). No significant associations with risk for AD or any of the studied biomarkers could be found in this study, thus not supporting VEGF as being a major risk gene for AD.
  • Ray, Sandip, et al. (författare)
  • Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
  • 2007
  • Ingår i: NATURE MEDICINE. - 1078-8956. ; 13:11, s. 1359-1362
  • Tidskriftsartikel (refereegranskat)abstract
    • A molecular test for Alzheimer's disease could lead to better treatment and therapies. We found 18 signaling proteins in blood plasma that can be used to classify blinded samples from Alzheimer's and control subjects with close to 90% accuracy and to identify patients who had mild cognitive impairment that progressed to Alzheimer's disease 2-6 years later. Biological analysis of the 18 proteins points to systemic dysregulation of hematopoiesis, immune responses, apoptosis and neuronal support in presymptomatic Alzheimer's disease.
  • Sjölander, Annica, 1969-, et al. (författare)
  • BACE1 gene variants do not influence BACE1 activity, levels of APP or Abeta isoforms in CSF in Alzheimer's disease.
  • 2010
  • Ingår i: Molecular neurodegeneration. - 1750-1326. ; 5:1
  • Tidskriftsartikel (refereegranskat)abstract
    • The BACE1 gene encodes the beta-site APP-cleaving enzyme 1 and has been associated with Alzheimer's disease (AD). BACE1 is the most important beta-secretase responsible for the generation of Alzheimer-associated amyloid beta-proteins (A beta) and may play a role in the amyloidogenic process in AD. We hypothesized that BACE1 gene variants might influence BACE1 activity or other markers for APP metabolism in the cerebrospinal fluid (CSF) and thereby contribute to the development of AD. We genotyped a Swedish sample of 269 AD patients for the rs638405 single nucleotide polymorphism (SNP) in the BACE1 gene and correlated genotype data to a broad range of amyloid-related biomarkers in CSF, including BACE1 activity, levels of Ab40, A beta(42), alpha- and beta-cleaved soluble APP (alpha-sAPP and beta-sAPP), as well as markers for Alzheimer-type axonal degeneration, i.e., total-tau and phospho-tau181. Gene variants of BACE1 were neither associated with amyloid-related biomarkers, nor with markers for axonal degeneration in AD.
  • Stomrud, Erik, et al. (författare)
  • Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults.
  • 2010
  • Ingår i: Archives of neurology. - 1538-3687. ; 67:2, s. 217-23
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Abnormal cerebrospinal fluid (CSF) biomarker levels predict development of Alzheimer disease with good accuracy and are thought to precede cognitive deterioration. OBJECTIVE: To investigate whether changes in CSF biomarker levels over time in healthy older adults are associated with a concurrent decline in cognitive performance. DESIGN: Retrospective analysis of longitudinal CSF biomarker levels and clinical data. SETTING: A combined academic dementia disorder research center and dementia clinic. PARTICIPANTS: Thirty-seven cognitively healthy older volunteers (mean age, 73 years). MAIN OUTCOME MEASURES: Longitudinal CSF total tau protein, hyperphosphorylated tau protein 181, and beta-amyloid(1-42) protein levels and cognitive assessments at baseline and at follow-up 4 years later. RESULTS: Low levels of CSF beta-amyloid(1-42) protein at follow-up were associated with decreased delayed word recall score on the Alzheimer Disease Assessment Scale-cognitive subscale (r(s) = -0.437, P < .01) and with slower results on A Quick Test of Cognitive Speed (r(s) = -0.540, P < .001). Individuals with a decrease during the 4-year study of 15% or more in CSF beta-amyloid(1-42) protein level performed worse on the Alzheimer Disease Assessment Scale-cognitive subscale delayed word recall (z = -2.18, P < .05) and A Quick Test of Cognitive Speed (z = -2.35, P < .05) at follow-up. An increase over time of 20% or more in CSF hyperphosphorylated tau protein 181 level correlated with slower results on A Quick Test of Cognitive Speed at follow-up (z = -2.13, P < .05). Furthermore, the presence of the APOE-epsilon4 (OMIM 107741) allele was associated with a greater longitudinal decrease in CSF beta-amyloid(1-42) protein level (chi(2) = 10.47, P < .05) and with a higher CSF total tau protein level at follow-up (chi(2) = 8.83, P < .05). No correlation existed between baseline CSF biomarker levels and baseline or follow-up cognitive scores. CONCLUSIONS: In this group of healthy older adults, changes in CSF biomarker levels previously associated with Alzheimer disease correlated with a decline in cognitive functions. Changes in CSF biomarker levels may identify early neurodegenerative processes of Alzheimer disease.
  • Sundelöf, Johan, et al. (författare)
  • Cystatin C Levels are Positively Correlated with both Aβ42 and Tau Levels in Cerebrospinal Fluid in Persons with Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Controls
  • 2010
  • Ingår i: Journal of Alzheimer's Disease. - 1387-2877. ; 21:2, s. 471-478
  • Tidskriftsartikel (refereegranskat)abstract
    • Cystatin C is suggested to be involved in neurodegeneration and the development of Alzheimer's disease (AD) by binding to soluble amyloid-beta (Abeta) peptides. Studies of cystatin C levels in cerebrospinal fluid (CSF) in relation to risk of AD are conflicting and relations between cystatin C, Abeta42, and tau levels in CSF in AD, mild cognitive impairment (MCI), and healthy controls are unknown. The objective of this study was to investigate cystatin C, Abeta42, and tau levels in CSF in AD, MCI, and controls. As a secondary aim, the relationships between cystatin C, Abeta42, and tau levels across disease groups were investigated. Cystatin C, Abeta42, total tau, and phosphorylated tau levels in CSF were analyzed by turbidimetry (cystatin C) and xMAP Luminex technology (Abeta and tau) in persons with AD (n=101), MCI (n=84), and healthy control subjects (n=28). Mean cystatin C levels were similar in cases of AD (5.6 mumol/L +/- 1.7), MCI (5.4 mumol/L +/- 1.48), and controls (5.6 mumol/L +/- 1.6). However, CSF cystatin C levels were strongly and positively correlated with total tau and phosphorylated tau levels (r=0.61-0.81, p< 0.0001) and Abeta42 (r=0.35-0.65, p< 0.001) independent of age, gender, and APOE genotype. Mean CSF cystatin C levels did not differ between patients with AD and MCI and healthy controls. Interestingly, cystatin C levels were positively correlated with both tau and Abeta42 levels in CSF independent of age, gender, and APOE genotype.
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 16
fritt online (4)
Typ av publikation
tidskriftsartikel (16)
Typ av innehåll
refereegranskat (15)
övrigt vetenskapligt (1)
Blennow, Kaj, 1958-, (15)
Zetterberg, Henrik, ... (12)
Hansson, Oskar (8)
Londos, Elisabet (6)
Andreasen, Niels (4)
visa fler...
Wallin, Anders, 1950 ... (4)
Palmer, Mona Seibt (3)
Skoog, Ingmar, 1954- ... (3)
Bogdanovic, Nenad (3)
Zetterberg, Madelein ... (3)
Andersson, Malin E, ... (3)
Buchhave, Peder (3)
Landgren, Sara, 1980 ... (3)
Lundh, Thomas (2)
Gustafson, Deborah, ... (2)
Andreasson, Ulf, 196 ... (2)
Sjölander, Annica, 1 ... (2)
Sjolander, Annica (2)
Gerhardsson, Lars, 1 ... (2)
Nilsson, Staffan, 19 ... (1)
von Otter, Malin, 19 ... (1)
Larsson, Anders, (1)
Gustafson, L (1)
Bergström, Petra, (1)
Sundström, Johan, (1)
Janciauskiene, Sabin ... (1)
Thelle, Dag, 1942- (1)
Sundstrom, J (1)
Nilsson, Michael, 19 ... (1)
Eriksdotter-Jönhagen ... (1)
Eriksdotter-Jonhagen ... (1)
Jern, Christina, 196 ... (1)
Jood, Katarina, 1966 ... (1)
Tasa, Gunnar (1)
Lannfelt, Lars, (1)
Ingelsson, Martin, (1)
Basun, Hans, (1)
Giedraitis, Vilmanta ... (1)
Kilander, Lena, (1)
Hammarsten, Ola, (1)
Umek, Robert M (1)
Nexo, Ebba (1)
Boxer, Adam, (1)
Karydas, Anna, (1)
Boström, Fredrik (1)
Stomrud, Erik (1)
Celojevic, Dragana, ... (1)
Sjögren, Magnus (1)
Degerman Gunnarsson, ... (1)
visa färre...
Göteborgs universitet (16)
Karolinska Institutet (5)
Chalmers tekniska högskola (1)
Uppsala universitet (1)
Engelska (16)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (16)
Naturvetenskap (1)


pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy